Hospital News
Return to Blood Cancer Overview
More on Blood Cancer
- Bexxar Effective as First-Line Treatment for Non-Hodgkin's Lymphoma Patients When Used With Chemotherapy
- Children With Advanced Hodgkin's Disease Respond Favorably to New Drug Regimen
- Clinical Trial for a Novel Multiple Myeloma Vaccine Begins at New York Weill Cornell Medical Center
- Columbia Receives $3 Million Award From Pediatric Cancer Foundation for New Research Laboratory
- Combination of Abbreviated Chemotherapy with Radioactive Monoclonal Antibody Effective in Previously Untreated Non-Hodgkin's Lymphoma
- Coping With Chronic Cancer Pain
- Do Heart Disease and Cancer Have a Common Genetic Link?
- Dr. Selina Chen-Kiang Honored as Researcher of the Year by the Leukemia and Lymphoma Society
- Gleevec May Be Effective Against a Second Blood Disease, According to Study To Be Presented at Hematology Meeting
- Health Effects of Secondhand Smoke Studied in First-of-Its-Kind Series of Clinical Studies
- Helping Parents Do the Right Thing: New Guidelines on Umbilical Cord Blood Banking
- Integrative Therapies Program for Children with Cancer at Morgan Stanley Children's Hospital of NewYork-Presbyterian Receives Gift Commitment from Origins Natural Resources
- Latest Findings Presented at Second International Symposium on Pediatric Non-Hodgkin's Lymphoma
- Message to the Elderly: It's Never Too Late to Prevent Illness!
- Multiple Myeloma Oral Therapy REVLIMID Approved by FDA
- New Anti-Leukemia Drug Significantly Improves Survival Even for Patients With Late-Stage Disease, Study Finds
- New Book by Weill Cornell Psychiatrist Offers Insight and Hope for "Surviving Cancer Emotionally"
- NewYork-Presbyterian/Weill Cornell Creates World-Class Cancer Center
- NewYork-Presbyterian/Weill Cornell Multiple Myeloma Program Begins Clinical Trial of Promising New Chemotherapy Cocktail with Revlimid
- NewYork-Presbyterian/Weill Cornell Seeks Patients with Mantle Cell Lymphoma for Clinical Trial with Velcade (Bortezomib) for Injection
- NewYork-Presbyterian Hospital/Columbia University Medical Center Physician-Scientists Present at American Society of Clinical Oncology 44th Annual Meeting
- NewYork-Presbyterian Hospital's Weill Cornell Medical Center Announces Preliminary Lung Cancer Data Involving Patients Treated With Arthritis Medication
- NewYork-Presbyterian Hospital and Columbia University Medical Center Physicians-Scientists Present Latest Cancer Findings at American Society of Hematology Meeting
- NewYork-Presbyterian Hospital Oncologists, from Columbia, Weill Cornell, Co-Lead World's Largest Lymphoma Forum for Patients
- One of the Nation's Largest Portfolios of New Lymphoma Therapies Targets Diverse and Difficult Cancer
- The Seventh Issue of Cancer Prevention Has Arrived!
- Tumor Size Predicts Survival in Most Common Type of Lung Cancer
- Two Novel Biologics Studied for Multiple Myeloma
- Weill Cornell Medical College Wins $7.5 Million Grant From Leukemia Society To Study Multiple Myeloma
- Weill Cornell Physician-Scientists Present Latest Cancer and Blood Findings at American Society of Hematology (ASH) Meeting
- Weill Cornell Researchers Report "Encouraging" Results with First Combination Antibody Therapy for Lymphoma
Health Library
Return to Blood Cancer Overview
More on Blood Cancer
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Bone Marrow Transplantation
- Cancer: Overview of Diagnostic Procedures
- Cancer Overview
- Cancer Rehabilitation
- Cancer Treatment Protocols
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Cutaneous T-Cell Lymphoma
- Cytology
- External Beam Therapy
- Grading and Staging of Cancer
- Hodgkin's Disease
- Leukemia Overview
- Myeloma Bone Disease / Multiple Myeloma
- Non-Hodgkin's Lymphoma
Clinical Services
Return to Blood Cancer Overview
More on Blood Cancer
- Adult Bone Marrow Transplant
- Bladder Cancer
- Blood and Bone Marrow Transplant
- Brain Cancer
- Center for Holistic Urology
- Center for Lymphoma and Myeloma
- Colon Cancer
- Early Lung Cancer Action Program
- Edward S. Harkness Eye Institute
- Esophageal Cancer
- Eye Cancer
- Gastrointestinal Cancer
- Gynecological Cancer
- Head and Neck Cancer
- Hematology (Blood Disorders)
- Kidney Cancer
- Leukemia and Myeloproliferative Disease Center
- Liver Cancer
- Lung Cancer
- Mesothelioma
- Oncology (Cancer)
- Pancreatic and Biliary Cancer
- Pediatric Cancer
- Prostate Cancer
- Rectal Cancer
- Robert M. Ellsworth Ophthalmic Oncology Center
- Soft Tissue and Bone Cancer
- Spirit of Care Program
- Stomach Cancer
- Testicular Cancer
- Urologic Cancer
Blood Cancer
The NewYork-Presbyterian Cancer Centers offer comprehensive programs in the diagnosis and treatment of hematological malignancies, with oncology specialists in lymphoma and multiple myeloma, as well as various types of leukemias and myelodysplastic syndromes. Patients benefit from the programs and resources offered at both NewYork-Presbyterian Hospital/Columbia University Medical Center and NewYork-Presbyterian Hospital/Weill Cornell Medical Center, including state-of-the-art treatment protocols involving new therapeutic agents derived from the Centers' major investment in basic and clinical research.
Diagnostic Innovations
Decisions about treatment involve the Hospital's world-class diagnostic services, which incorporate the fields of hematology, pathology, molecular biology, immunology, radiology, and nuclear medicine. The diagnostic pathology group of NewYork-Presbyterian Cancer Centers is widely regarded as among the world's best group of hematopathologists, particularly in the area of lymphoma.
Therapeutic Excellence
Advances in the treatment of hematological cancers are the result of integrated teamwork among many oncology specialists at NewYork-Presbyterian Cancer Centers. The Centers' physicians are committed to reducing toxicity related to treatments, and making sure that patients have access to all major therapeutic options, including chemotherapy, radiation therapy, monoclonal antibody therapy, and autologous and allogeneic blood and marrow transplantation.
Vaccine Therapies
Through its Cellular Immunotherapy Research Laboratory, NewYork-Presbyterian/Columbia is exploring vaccine therapies for treating a number of different hematological malignancies. The vaccine therapy is administered after a patient has had a transplant and completed a chemotherapy regimen. The goal is to trigger an immune response that will destroy any remaining malignancy. NewYork-Presbyterian/Weill Cornell is a leading institution in the development of vaccines immunotherapies. Calling on the body's own immune cells and antibodies to fight the cancers, these therapies use a particular antigen (target) derived from the cancer cell, or work by creating genetic material for the cell that will attract an immune response. These immune system vaccines show great promise in fighting cancers and preventing recurrence. For lymphoma, the Medical Center also is a leading center in a Phase III clinical trial that may establish the ultimate clinical benefit for these techniques.
Genetics
Many approaches to genetic treatment of hematological cancers are being examined, including the use of antisense agents. These agents are designed to block the "instructions" inside a cell that result in its malignant growth.
Single and Combination Therapies for Hematological Malignancy At NewYork-Presbyterian/Columbia, a comprehensive program for hematological malignancies includes individualized chemotherapy treatments, innovative antibody and small molecule clinical trials, and an integrated stem cell transplantation program. The expertise of its physicians has led NewYork-Presbyterian/Columbia to be named a National Center for Excellence in myelodysplastic syndromes and leukemia. One area of investigation includes the use of chemotherapy and antibody combinations for treatment of leukemias and lymphomas in an attempt to minimize toxic effects of treatment and take advantage of combined clinical efficacy against tumors. Excellent results have been achieved in treating patients with chronic lymphocytic leukemia, low-grade lymphomas, and Waldenstrom's macroglobulinemia. A trial for patients with relapsed leukemia and myelodysplastic syndromes is in progress using a new antibody/chemotherapy combination.
Drug Therapies
A greater understanding of the biology of blood and lymphatic cancers has given rise to more precisely calibrated combinations of drug therapies or combinations of drug and radiation therapies, which may achieve improved outcomes for patients. The strength of the leukemia programs at both NewYork-Presbyterian/Weill Cornell and NewYork-Presbyterian/Columbia has led to their collaboration in a major multi-institutional National Cancer Institute-sponsored research protocol for relapsed leukemias using bryostatin, a chemotherapy-enhancing agent. Small molecules, developed at NewYork-Presbyterian/Columbia, now are available for use in clinical trials with chemotherapy for myeloma, chronic leukemias, and lymphomas. NewYork-Presbyterian/Weill Cornell has been a leading site for the development of Gleevec, a new type of treatment for chronic myelogenous leukemia that now is a standard treatment for the disease. More than 40 different drugs now are being used in the treatment of hematological diseases, and drug development efforts at the Hospital are evaluating scores of new agents that ultimately may impact treatment outcomes for cancer patients.
